AnalystsMaury RaycroftMaury Raycroft's Stock Forecasts
AnalystsMaury Raycroft
Analyst Ranking
Bottom 14%
#3647 out of 4204 analysts
Average Return
-12.64%
Win Rate
22%6 out of 27
Risk vs Reward
Poor
Good
Maury Raycroft's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Reata Pharmaceuticals IncRETA | +198.41% | $28.93 | $86.33 | 2017-08-30 - 2018-08-30 | Strong Buy |
Arrowhead Pharmaceuticals IncARWR | +157.02% | $6.91 | $17.76 | 2018-03-27 - 2019-03-27 | Strong Buy |
Tyra Biosciences IncTYRA | +88.64% | $15.40 | $29.05 | 2021-10-11 - 2021-11-08 | Strong Buy |
Biocryst Pharmaceuticals IncBCRX | +54.64% | $4.96 | $7.67 | 2017-09-06 - 2018-09-06 | Strong Buy |
Tyra Biosciences IncTYRA | +32.51% | $11.32 | $15.00 | 2022-03-08 - 2023-03-07 | Strong Buy |
Maury Raycroft Analyst Color
Get additional color on Maury Raycroft's coverage of popular stocks
Maury Raycroft's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Compass Therapeutics IncCMPX | 1 | Strong Buy | $8.00 | +149.22% | Initiates Coverage On | 2 months ago |
Vera Therapeutics IncVERA | 2 | Hold | $6.00 | -19.79% | Downgrades | 3 months ago |
Arrowhead Pharmaceuticals IncARWR | 2 | Strong Buy | $75.00 | +199.28% | Maintains | 4 months ago |
Imago Biosciences IncIMGO | 2 | Hold | $36.00 | -0.03% | Downgrades | 4 months ago |
Alnylam Pharmaceuticals IncALNY | 1 | Strong Buy | $232.00 | +23.72% | Maintains | 6 months ago |
Rezolute IncRZLT | 1 | Strong Buy | $11.00 | +447.26% | Initiates Coverage On | 6 months ago |
Forma Therapeutics Holdings IncFMTX | 1 | Hold | $20.00 | -0.05% | Downgrades | 7 months ago |
Sierra Oncology IncSRRA | 1 | Hold | $55.00 | +0.02% | Downgrades | a year ago |
Tyra Biosciences IncTYRA | 3 | Strong Buy | $27.00 | N/A | Upgrades | a year ago |
Allakos IncALLK | 1 | Hold | N/A | N/A | Downgrades | a year ago |
Beyondspring IncBYSI | 2 | Hold | $5.00 | N/A | Downgrades | a year ago |
Ayala Pharmaceuticals IncAYLA | 1 | Strong Buy | $17.00 | N/A | Upgrades | a year ago |
Theseus Pharmaceuticals IncTHRX | 1 | Strong Buy | $23.00 | N/A | Initiates Coverage On | a year ago |
Celcuity IncCELC | 1 | Strong Buy | $48.00 | N/A | Initiates Coverage On | 2 years ago |
Biocryst Pharmaceuticals IncBCRX | 2 | Hold | N/A | N/A | Downgrades | 2 years ago |
Aslan Pharmaceuticals LtdASLN | 1 | Strong Buy | $8.00 | N/A | Initiates Coverage On | 2 years ago |
Valneva SeVALN | 1 | Strong Buy | $36.00 | N/A | Initiates Coverage On | 2 years ago |
Solid Biosciences IncSLDB | 1 | Strong Buy | $7.00 | N/A | Initiates Coverage On | 2 years ago |
Mirati Therapeutics IncMRTX | 1 | Strong Buy | $196.00 | N/A | Upgrades | 2 years ago |
Crispr Therapeutics AgCRSP | 1 | Strong Buy | $172.00 | N/A | Upgrades | 2 years ago |
Chimerix IncCMRX | 1 | Strong Buy | $21.00 | N/A | Initiates Coverage On | 2 years ago |
Checkmate Pharmaceuticals IncCMPI | 1 | Strong Buy | $22.00 | N/A | Initiates Coverage On | 3 years ago |
Calliditas Therapeutics AbCALT | 1 | Strong Buy | $44.00 | N/A | Initiates Coverage On | 3 years ago |
Black Diamond Therapeutics IncBDTX | 1 | Strong Buy | $47.00 | N/A | Initiates Coverage On | 3 years ago |
Affimed NvAFMD | 1 | Strong Buy | $4.00 | N/A | Upgrades | 5 years ago |
Kezar Life Sciences IncKZR | 1 | Strong Buy | $23.00 | N/A | Initiates Coverage On | 5 years ago |
Intellia Therapeutics IncNTLA | 1 | Strong Buy | $42.00 | N/A | Maintains | 5 years ago |
Reata Pharmaceuticals IncRETA | 1 | Strong Buy | $44.00 | N/A | Initiates Coverage On | 6 years ago |
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.